Latest news and press releases about Cardiff Oncology, Inc. (CRDF): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Price
| Price | $1.35 |
| Market Cap | $104M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.63 |
| EV / EBITDA | -1.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -103.08% |
| Return on Invested Capital | -156.60% |
| Return on Assets | -107.29% |
| Gross Margin | 100.00% |
| Operating Margin | -8320.08% |
| Net Margin | -7884.06% |
Related companies: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of CRDF: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks